Is PathAI worth it for a large anatomic pathology lab?

If your slides are already digitized, yes — AISight Dx holds FDA 510(k) clearance for primary diagnosis (announced June 30, 2025), so AI-assisted reading sits inside a cleared workflow rather than beside it, and the MedStar Health (April 2026) and Labcorp (February 2026) deployments show the model works at health-system scale. If your slides are still on glass, the value does not start yet.

How does PathAI compare to Paige?

Both target the diagnostic side of computational pathology. PathAI's distinction is the combination of AISight Dx FDA clearance for primary diagnosis with AIM-MASH, the first AI-powered tool to receive FDA qualification for MASH clinical trials (December 09, 2025), plus CE-IVDR marking. Paige is the comparison buyers most often run; weigh the specific cleared algorithms each vendor offers against the indications you actually read.

How does PathAI compare to Lunit?

Lunit is the comparison that comes up on the research side, where PathAI's AIM-HI UC and IBDExplore (launched February 11, 2026) and its IHCExplore and IBDExplore research tools compete. If your workload is clinical diagnosis, PathAI's AISight Dx FDA clearance is the more relevant credential; if it is research throughput, compare the specific research algorithms each vendor publishes.

What are PathAI's biggest limitations?

It requires digitized slides — no scanning, no value. Deployment is cloud-native, so on-premise-only organizations are excluded. The catalog is targeted rather than general-purpose, meaning you license biomarker-specific algorithms such as AIM-PDL1, AIM-HER, AIM-ER and METPredict rather than one model that does everything. And PathAI has entered a definitive merger agreement to be acquired by Roche, which can shift roadmap priorities at renewal.

What is AIM-MASH and why does FDA qualification matter?

AIM-MASH is PathAI's AI assist for MASH clinical trials, and on December 09, 2025 it became the first AI-powered tool to receive FDA qualification for that setting. Qualification means the tool can be used to generate standardized histopathology endpoints in trials, which is a materially different posture from a research-grade algorithm. If you run MASH studies, it is the single most relevant item in PathAI's catalog.

Is PathAI good for biopharma clinical trial endpoints?

PathAI reports that 90% of the top 15 biopharma companies use its technology, and its trial-facing algorithms target named endpoints: AIM-MASH for MASH, AIM-HI UC and IBDExplore for ulcerative colitis and IBD histopathology (added February 11, 2026), and AIM-PDL1, AIM-HER, AIM-ER and METPredict for biomarker quantification. The 450+ pathologist contributor network and 32.5M+ annotations sit behind algorithm validation.

Can PathAI replace a general-purpose pathology AI tool?

Not in the way that question usually means. PathAI is deliberately a catalog of targeted algorithms — TumorDetect, ArtifactDetect, PathAssistDerm, METPredict and the AIM biomarker set — running inside the AISight workflow hub. If you want one model to cover everything, that is not this platform. If you want indication-specific algorithms with regulatory backing, the targeting is the point rather than a gap.

How long does PathAI take to set up?

It depends entirely on your starting point. A lab with slide scanning and pathology IT already in place faces a multi-week implementation for image pipeline and workflow configuration; a biopharma group running one algorithm still has to wait on trial timelines. If you have no digitized slides, setup is not the constraint — getting to digital is.

Does PathAI integrate with existing lab systems?

AISight is positioned as an open enterprise workflow solution that acts as a central hub for case management, image management and AI applications, which is the integration story PathAI publishes. Detailed system-to-system integration documentation is not publicly available, so ask for the interface list during evaluation and confirm it covers your LIS and image archive before you commit.

What does the Roche acquisition mean for PathAI customers?

PathAI has entered a definitive merger agreement to be acquired by Roche, announced on its own homepage. For existing customers the practical questions are roadmap continuity for the algorithms you license, support terms after close, and whether contract terms change at renewal. The clinical platform — AISight Dx with FDA clearance for primary diagnosis — is the asset Roche is buying, so continuity is the likely direction, but get it in writing.

Healthcare

PathAI

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

74/100Safe BetCustom pricingContact Sales

PathAI's edge is regulatory, not marketing: AISight Dx cleared for primary diagnosis plus an FDA-qualified MASH algorithm is a combination few rivals can currently match. The Labcorp and MedStar wins show it scales inside real health systems. But this is enterprise infrastructure — if your slides aren't digitized and you can't absorb an integration cycle, the algorithm catalog will sell you something you can't run.

Verified 4d ago · liveness 74/100 · cite: rightaichoice.com/tools/pathai

Best for

Large anatomic pathology labs with digital slide scanning already in place
Biopharma translational teams needing AI biomarker quantification for trials
Academic medical centers running regulated digital pathology workflows
Sponsors designing MASH, ulcerative colitis or IBD studies with standardized endpoints

Not ideal for

Small labs with no digitized slide scanning infrastructure
Organizations that require on-premise rather than cloud deployment
Teams wanting one general-purpose pathology model instead of a targeted algorithm catalog

Visit Website

AdvancedLarge labs with scanning already deployed and an IT team to spare: expect a multi-week implementation covering image pipeline and workflow configuration. Biopharma groups running a specific algorithm: the algorithm side is faster than the platform side, but trial timelines still gate first usable output. Small practices without digitized slides: not applicable until scanning exists.Web · APIAPI available3.5k viewsVerified 4d ago

Pricing

Custom pricing

Contact Sales5 hidden costs

Learning curve

Advanced

Large labs with scanning already deployed and an IT team to spare: expect a multi-week implementation covering image pipeline and workflow configuration. Biopharma groups running a specific algorithm: the algorithm side is faster than the platform side, but trial timelines still gate first usable output. Small practices without digitized slides: not applicable until scanning exists.

Runs on

WebAPI

API available

Who it's for

Anatomic pathology lab directorBiopharma translational leadAcademic medical center research group

Live sentiment

Is PathAI actually worth it?

We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.

Honest verdict, not marketing
Real pros & cons from real users
Attributed quotes with receipts

Run a free scan

3 free scans · no card needed

Skip it if

Skip PathAI if your slides are not already digitized or if you need an on-premise deployment — the algorithms only start working after both of those boxes are ticked.

The 30-second take

Biggest gripe

Biomarker algorithms are licensed separately from the AISight platform, so the catalogue you actually need drives the bill more than the base workflow does.

Price reality

PathAI sells to large anatomic pathology labs, academic medical centers and biopharma translational groups, so the commercial shape fits organizations with an existing slide-scanning fleet and a procurement process. Smaller labs without digitized slides are priced out before the algorithm catalog becomes relevant. Diagnostic-side comparisons land on Paige; research-side comparisons land on Lunit. Confirm current commercial terms directly, since the pending Roche acquisition may affect them.

In short

PathAI — PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials. Best for Large anatomic pathology labs with digital slide scanning already in place, Biopharma translational teams needing AI biomarker quantification for trials, Academic medical centers running regulated digital pathology workflows. Contact Sales pricing.

No head-to-head comparison for PathAI yet — the alternatives below are the closest matches we list.

What people actually say about PathAI — is it worth it?

We scanned public community sources for PathAI on Oct 14, 2026 and could not establish that the discussion we found is about this tool rather than something else sharing its name. Only 0 of the posts we fetched could be positively tied to PathAI. Rather than publish a sentiment score built on the wrong subject, we publish nothing here and re-run the scan.

Viability Score

74/100

Safe Bet

How well maintained and how widely used is PathAI? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this

Recent activity

Traction

Site health

User sentiment

What the vendor publishes

Last calculated: October 2026

How we score →

Key Features

AISight cloud-native digital pathology workflow platform
AISight Dx FDA 510(k) cleared for primary diagnosis (June 30, 2025)
CE-IVDR marked for regulated diagnostic workflows
Open platform hub for case management and image management
Hosts third-party and PathAI AI applications
AIM-PDL1 biomarker quantification
AIM-HER biomarker quantification
AIM-ER biomarker quantification
TumorDetect automated tumor detection
ArtifactDetect slide artifact detection
PathAssistDerm dermatopathology AI
METPredict MET expression analysis
AIM-MASH for MASH clinical trials (FDA qualified, Dec 09, 2025)
AIM-HI UC for ulcerative colitis histopathology endpoints
IBDExplore for inflammatory bowel disease research

About PathAI

Contact SalesAdvancedAPI availableWeb · API

PathAI sells an enterprise digital pathology platform — AISight — to biopharma companies and anatomic pathology laboratories. AISight is a cloud-native, open workflow hub that handles case management and image management and hosts histopathology AI from PathAI and third parties. That openness matters: labs plug in a mix of algorithms rather than betting on a single vendor's research pipeline. The algorithm catalog is why most buyers show up. AIM-PDL1, AIM-HER and AIM-ER quantify biomarkers; TumorDetect finds tumor automatically; ArtifactDetect flags slide artifacts; PathAssistDerm covers dermatopathology; METPredict handles MET expression. AISight Dx adds the clinical layer — it received FDA 510(k) clearance for primary diagnosis on June 30, 2025, and holds CE-IVDR marking, so the AI reads inside a regulated diagnostic workflow instead of beside it. Clinical trials are the fastest-moving side. AIM-MASH became the first AI-powered tool FDA-qualified for MASH trials in December 2025, and the February 11, 2026 launch of AIM-HI UC and IBDExplore extended standardized histopathology endpoints to ulcerative colitis and inflammatory bowel disease studies. PathAI also runs a proprietary pathologist contributor network — the site now cites 500+ board-certified pathologists and 42.5M+ annotations — and says 90% of the top 15 biopharma companies use its technology. Deployment happens through named health-system and reference-lab deals rather than signups: Labcorp expanded on February 23, 2026 to push the FDA-cleared platform across its national network, and MedStar Health announced an April 07, 2026 rollout of AISight Dx with PathAI's advanced AI applications. Position it as regulated infrastructure for organizations that already scan slides — not a plug-and-play tool for a lab still on glass.

Behind the Verdict

We'd reach for PathAI when the deliverable has to survive scrutiny — a regulated primary diagnosis workflow, or a trial endpoint a reviewer will question. That is where the FDA clearance on AISight Dx and the FDA qualification on AIM-MASH actually earn their keep. For a biopharma translational group running MASH, UC or IBD studies, the recently added AIM-HI UC and IBDExplore endpoints are the specific reason to shortlist now rather than next year.Pass if you are still converting glass slides. A small lab buying on the strength of the algorithm list alone will end up with shelfware.Against alternatives, the split is philosophical. Diagnostic-first shops that want a scanner-to-reader stack often price Paige. Research-first teams that prioritize a broad oncology biomarker portfolio look at Lunit. PathAI's bet is different: one open hub where third-party algorithms coexist with its own, backed by a contributor network of 500+ pathologists and 42.5M+ annotations.Watch the corporate picture. PathAI has entered a definitive merger agreement to be acquired by Roche, so procurement should plan for ownership and roadmap changes during contracting. Ask hard questions about data portability and algorithm licensing before you commit.Also budget for the peripherals: digital scanners, LIS integration, validation studies and pathologist retraining are rarely in the platform conversation and usually dwarf the subscription. In practice the platform decision is the easy part.

Researching PathAI? Get your full AI stack in 60 seconds.

Free, no signup — tell us your goal and get tools matched to your budget & existing stack.

Real-world workflow fit

Concrete scenarios for the personas PathAI actually fits — and what changes day-one when you adopt it.

Anatomic pathology lab director

Digitized slides flow into AISight for case and image management, pathologists read with AISight Dx cleared for primary diagnosis, and TumorDetect plus ArtifactDetect pre-screen cases before a human signs off.

Outcome: Faster case triage and a defensible audit trail, with primary diagnosis running inside a cleared workflow rather than beside it.

Biopharma translational lead

Trial tissue is scanned, then AIM-PDL1, AIM-HER, AIM-ER or METPredict quantify the relevant biomarker while AIM-MASH or AIM-HI UC standardizes the histopathology endpoint for the protocol.

Outcome: Reproducible, regulator-facing endpoint measurements instead of site-to-site pathologist variability.

Academic medical center research group

The team runs IHCExplore and IBDExplore over archival slides to characterize cohorts, using the 32.5M+ annotation base behind the algorithms as validation context.

Outcome: High-volume retrospective studies without building an in-house computational pathology stack.

Use Cases

Pathologists reviewing cancer biopsies with AI assistance to reduce diagnostic time
Biopharma companies analyzing tissue samples for clinical trial endpoints
Labs quantifying PDL1, HER2 and ER biomarkers for treatment decisions
Hospitals aiming to reduce turnaround times for pathology reports
Research institutions running MASH, IBD or ulcerative colitis histopathology studies

Limitations

The platform only delivers value once your slides are digitized, so labs without slide scanning cannot use it.
Deployment is cloud-native, which rules out organizations that must keep images on-premise.
The algorithm catalog is targeted rather than general-purpose — you assemble biomarker-specific tools rather than buying one model that covers everything.
Delivery is vendor-dependent with dedicated support, so timelines partly follow PathAI's schedule rather than yours.
Corporate risk is real: PathAI has entered a definitive merger agreement to be acquired by Roche, and acquisitions of this type typically reshuffle roadmap priorities toward the acquirer's diagnostics franchise, so multi-year commitments should be discussed explicitly.

as of 2026-10-01

Verification history

We have re-verified PathAI 23 times since May 17, 2026. Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.

Oct 18, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Oct 12, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Sep 14, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Aug 30, 2026 — re-checked, vendor evidence unchanged
Aug 23, 2026 — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Aug 15, 2026 — re-checked, vendor evidence unchanged

Showing the 6 most recent of 23 verification passes.

Free to cite with attribution — this page re-verifies continuously.

Hidden costs & gotchas

What the public pricing page doesn't put in bold. Captured from pricing-page footnotes, contract terms, and recurring complaints.

Biomarker algorithms are licensed separately from the AISight platform, so the catalogue you actually need drives the bill more than the base workflow does.
Adding a new indication later (for example moving from PDL1 work into MASH or IBD endpoints) means a new algorithm order on top of your existing agreement.
Cloud-native image management means storage volume grows with your slide archive, and that growth is a recurring line rather than a one-time purchase.
Enterprise delivery runs through PathAI's implementation and support team, so internal pathology IT time is a hidden cost of the rollout.
The pending Roche acquisition may change contract terms and roadmap scope at renewal for algorithms you adopted before the deal closed.

Where the pricing makes sense

The company stage and team size where PathAI's pricing actually pencils out — and where peers do it cheaper.

Setup time & first value

How long it actually takes to get something useful out of PathAI — broken out by persona, not the marketing-page minute.

Switching to or from PathAI

How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.

Migrating in

→From manual microscope-only reading: deploy slide scanning first, then bring cases into AISight for case and image management.
→From a single-biomarker point tool: consolidate into AISight so biomarker algorithms run inside the same case workflow as primary diagnosis.
→From an on-premise image store: plan an explicit move to PathAI's cloud-native model, since on-premise deployment is not the fit here.

Migrating out

↗To Paige: migrate if your priority shifts to diagnostic-first AI and you need that vendor's specific clearance footprint.
↗To Lunit: migrate if your work is research-oriented and you want that vendor's research algorithm set.
↗To an in-house computational pathology stack: migrate only if you have the engineering and annotation resources to reproduce regulated algorithm performance.

Resources & Guides

Tutorials & Learning

YouTube returned 6 videos for “PathAI”, and we withheld 6: 6 could not be judged, because “PathAI” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about PathAI.